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Abstract
This study provides a parallel characterization of the cytokine and chemokine response to stroke in the human and
mouse brain at different stages of infarct resolution. The study goal was to address the hypothesis that chronic
inflammation may contribute to stroke-related dementia. We used C57BL/6 and BALB/c mice to control for strain
related differences in the mouse immune response. Our data indicate that in both mouse strains, and humans,
there is increased granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-6 (IL-6), interleukin-12
p70 (IL-12p70), interferon gamma-induced protein-10 (IP-10), keratinocyte chemoattractant/interleukin-8 (KC/IL-8),
monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), macrophage
inflammatory protein-1β (MIP-1β), regulated on activation, normal T cell expressed and secreted (RANTES), and
Tumor necrosis factor-α (TNF-α) in the infarct core during the acute time period. Nevertheless, correlation and two-
way ANOVA analyses reveal that despite this substantial overlap between species, there are still significant
differences, particularly in the regulation of granulocyte colony-stimulating factor (G-CSF), which is increased in
mice but not in humans. In the weeks after stroke, during the stage of liquefactive necrosis, there is significant
resolution of the inflammatory response to stroke within the infarct. However, CD68+ macrophages remain present,
and levels of IL-6 and MCP-1 remain chronically elevated in infarcts from both mice and humans. Furthermore,
there is a chronic T cell response within the infarct in both species. This response is differentially polarized towards
a T helper 1 (Th1) response in C57BL/6 mice, and a T helper 2 (Th2) response in BALB/c mice, suggesting that the
chronic inflammatory response to stroke may follow a different trajectory in different patients. To control for the
fact that the average age of the patients used in this study was 80 years, they were of both sexes, and many had
suffered from multiple strokes, we also present findings that reveal how the chronic inflammatory response to
stroke is impacted by age, sex, and multiple strokes in mice. Our data indicate that the chronic cytokine and
chemokine response to stroke is not substantially altered in 18-month old compared to 3-month old C57BL/6 mice,
although T cell infiltration is attenuated. We found a significant correlation in the chronic cytokine response to
stroke in males and females. However, the chronic cytokine response to stroke was mildly exacerbated by a
recurrent stroke in both C57BL/6 and BALB/c mice.
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Introduction
Stroke is the fifth leading cause of death in the United
States, although many patients survive. About 8 % of
those who survive go on to experience another stroke
within a year [32]. Of the seven million Americans cur-
rently living with the after effects of stroke, 30 % suffer
from delayed cognitive dysfunction, or dementia, that
worsens progressively after the stroke [1, 5, 29]. Patients
who develop dementia after stroke exhibit a leaky blood-
brain-barrier (BBB) and signs of increased inflammation
in their blood [22, 27, 43]. Those findings support the
hypothesis that a chronic inflammatory response to nec-
rotic brain tissue might be a cause of delayed cognitive
decline. However, a major challenge to testing this hy-
pothesis is that in both animal models and humans, nei-
ther the resolution nor the characteristics of late
inflammation after cerebral infarction are well defined
[17, 25, 26, 30, 31]. In rodents, most research to date has
focused on inflammation within the first few weeks after
stroke, the length of time it takes for the core of the in-
jury to be sealed by glial scarring [25, 26]. In humans,
there has been far less research and the long-term se-
quential pathology of inflammation in the brain after
ischemic stroke has only been described by histology
[31]. Although histology has revealed that there is
persistent immune cell infiltration, sometimes decades
after stroke, in approximately 40 % of human cerebral
infarcts, the identity of the immune cells and what
cytokines and chemokines they may be producing is
unknown [31].
It was recently demonstrated that there is a chronic
immune response to stroke that lasts for at least 7 weeks
in mice, and that targeting at least one component of
this response, the B cell component, can prevent the
development of delayed cognitive deficits [9]. As a
follow-up to that study, and to further address the
hypothesis that one of the mechanisms that contributes
to delayed cognitive dysfunction after stroke is a chronic
inflammatory response that persists at the site of the le-
sion, in turn causing bystander damage to surrounding
tissue, we present here a characterization of the cytokine
and chemokine response to stroke in the human brain at
different stages of infarction. To bridge this study
with preclinical stroke research we also characterized,
in parallel, the cytokine and chemokine response to
stroke in the mouse brain at different stages of infarc-
tion. We used mice since most basic and preclinical
stroke research is conducted in mouse models of
stroke. Furthermore, because there are significant dif-
ferences in the inflammatory response to disease and
injury in different mouse strains, we used two popular
strains, C57BL/6 and BALB/c, to control for mouse
strain-related heterogeneity in the inflammatory re-
sponse to stroke [4].
Nearly 75 % of all strokes occur in patients over the
age of 65 years, and approximately 25 % of the nearly
800,000 strokes experienced in the United States every
year are recurrent strokes [32]. Accordingly, the human
post-mortem tissue used in this study came from elderly
men and women, some of whom suffered from multiple
strokes. To control for this heterogeneity, and serve as
an additional bridge between clinical and preclinical
stroke research, we also present data that reveals how
the chronic inflammatory response to stroke is impacted
by age and sex in C57BL/6 mice, and by multiple strokes
in both C57BL/6 and BALB/c mice. Sieber and collegues
previously showed that increases of TNFα, IL-1β, MIP-
1α, MCP-1, and IL-6 are attenuated 7 days following
stroke in aged C57BL/6 mice, and that older mice have
smaller infarct volumes [42]. Other studies have shown
that the mechanisms of damage following stroke are
sexually dimorphic (reviewed in [23, 37]). However, no
studies have yet reported how the chronic cytokine and
chemokine response to stroke is altered in any animal
models of recurrent stroke.
Our findings reveal that there is substantial overlap in
the acute cytokine and chemokine response to stroke in
mice and humans, albeit there are key differences. For
example, in humans compared to mice, G-CSF and IL-6
appear differentially regulated. They also reveal that
there is substantial overlap in the chronic inflammatory
response to stroke, which our data suggest resolves more
slowly in the brain than in other tissues in both humans
and mice. However, there are still key differences, for ex-
ample, C57BL/6 mice develop a chronic Th1 polarized T
cell response, whereas BALB/c mice develop a chronic
Th2 polarized T cell response, and humans appear to be
more heterogeneous in their chronic adaptive immune
response to stroke than either strain.
Our findings also show that the inflammatory response
to stroke is remarkably consistent in aged mice, although
fewer T cells infiltrate the brain in aged animals, that it
significantly correlates in males and females, and that
the inflammatory response to a recurrent stroke is
mildly exacerbated in C57BL/6 and BALB/c mice. To-
gether, these data provide a resource for target validation
for preclinical stroke studies by providing a parallel map
of the cytokine and chemokine response to stroke during
different stages of infarct resolution in humans, as well
two commonly used mouse strains, in the presence and
absence of two common stroke co-morbidities.
Material and methods
Human tissue
Acute and chronic stroke infarcts dissected from fresh
frozen brain tissue (5 g blocks), along with location-
matched tissue from age-matched controls, were ob-
tained from the Banner Sun Health Research Institute
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(Sun City, AZ) [3], the University of California at Los
Angeles Human Brain and Spinal Fluid Resource Center
(Veterans Affairs, Greater Los Angeles Healthcare
System, Los Angeles, CA), and the University of Miami
Brain Endowment Bank (Miller School of Medicine,
Miami, FL). Tissue samples came from 55 post-mortem
brains; 33 samples came from patients with a clinical
and neuropathological diagnosis of either acute or
chronic stroke, and 23 samples from age-matched con-
trol patients. Samples came from brain regions mainly
comprising the frontal cortex and hippocampus, with
others from the temporal cortex, striatum, and internal
capsule. All patients with Alzheimer’s disease, Parkin-
son’s disease, Huntington’s disease, multiple sclerosis, or
any other confounding neurological disease were ex-
cluded. Both male and female patients were included.
The mean age at death was 79.9 years, and the mean
autolysis time was 13.2 h (see Table 1 for patient infor-
mation). The autolysis cut-off time for this study was
24 h. Research was conducted in compliance with pol-
icies and principles contained in the Federal Policy for
the Protection of Human Subjects. To determine if the
dissected lesions were at the stage of acute injury, li-
quefactive necrosis, or cystic encephalomalacia, tissue
samples were staged by cross-checking clinical infor-
mation with histological assessment by hematoxylin
and eosin (H&E) staining using standard techniques.
Tissue samples then underwent processing for immu-
nostaining and multiplex immunoassays (Fig. 1a).
Staging criteria
Lesions were classified as acute if there was evidence of
eosinophilic neurons, and if neuronal nuclei displayed
evidence of pyknosis and karyorrhexis. The classification
of acute was also confirmed by the presence of swollen,
faded glia and endothelial cells, and evidence of myelin
fiber disintegration. Lesions at the stage of liquefactive
necrosis were classified by the presence of foamy macro-
phages, and if around the periphery of the lesion, astro-
cytes had multiplied and developed interconnected
extensions to form the astroglial scar. Lesions were clas-
sified as at the stage of cystic encephalomalacia if there
was evidence that the lesion had been predominantly re-
sorbed leaving a cavity surrounded by a dense network
of glial fibers and blood vessels (Fig. 1b).
Mice
Adult male C57BL/6 mice and adult male BALB/c mice
(10–12 weeks old) were purchased from The Jackson
Laboratory (Bar Harbor, ME), with the exception of one co-
hort of male 18-month old C57BL/6 mice that were ob-
tained from the National Institute on Aging (Bethesda,
MD), and one cohort of female C57BL/6 mice (10-12 weeks
old) that were obtained from Harlan/Envigo (Indianapolis,
IN). All animals were housed under a 12-h light/dark sched-
ule with ad libitum access to food and water. All animal ex-
periments were designed to ensure humane endpoints and
minimize numbers of mice and suffering. Allocation of mice
into stroke and sham experimental groups was performed
randomly. Mice underwent stroke surgery at 12 weeks or
18 months of age. For mice that underwent two stroke sur-
geries, there was a recovery period of 3 weeks before the
second stroke surgery was performed on the side contralat-
eral to the first stroke. Mice were then euthanized at 24 h,
1 week, or 7 weeks following stroke. For euthanasia, mice
were intraperitoneally injected with a mixture of 100 mg/kg
ketamine, 20 mg/kg xylazine, and 3 mg/kg acepromazine,
and intracardinally perfused with 0.9 % saline. Brains were
extracted, and the infarct was dissected for flow cytometry,
or snap frozen in liquid nitrogen for multiplex immunoas-
says. Alternatively, whole brains were post-fixed in 4 % para-
formaldehyde for immunostaining.
Stroke surgery
In BALB/c mice, distal middle cerebral artery occlu-
sion (DMCAO) was performed, as previously de-
scribed [8]. Sham surgeries were identical to stroke
surgeries, except for ligation of the DMCA. C57BL/6
mice were given 9 % oxygen for 45 min immediately
after DMCAO. We refer to this variation of DMCAO
as DH stroke (DMCAO + hypoxia). This period of
hypoxia induces vasoconstriction and compensates for
extensive collateralization between the anterior cere-
bral artery and MCA present in C57BL/6 mice, and
makes stroke size in C57BL/6 mice equivalent to
stroke size in BALB/c mice following DMCAO alone
[8]. For all experiments mice were subcutaneously
injected with 0.1 mg/kg buprenorphine before surgery,
anesthesized with 1–3 % isoflurane inhalation during
surgery, and injected with 25 mg/kg cefazolin and
1 mg/kg buprenorphine SR immediately after surgery.
Mice that underwent sham DH stroke were also given
Table 1 Patient information
N = 55 patients Normal control patients Acute stroke patients Liquefactive necrosis patients Cystic encephalomalacia patients
Age in years (range) 77.4 (53–92) 76.2 (55–91) 86.8 (77–106)a 79.8 (62–92)
N (females/males) 23 (8/15) 5 (2/3) 18 (9/9) 9 (7/2)
Autolysis time in hours (range) 11.7 (2.8–24) 9.6 (3–23.9) 5.3 (2.3–9.5)b 6.8 (2.3–19.8)
ap ≤ 0.05 and bp ≤ 0.01 versus normal control patients as analyzed by a t-test and corrected for multiple comparisons
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9 % oxygen for 45 min immediately after surgery.
Core body temperature was maintained at 37 °C
throughout surgery and hypoxia in C57BL/6 mice.
Human immunohistochemistry
Human brain sections were immunostained using
standard techniques using an anti-CD20 (1:500; Dako,
Cirpinteria, CA), anti-CD3 (1:500; Dako), anti-CD4
(1:500; Ventana Medical Systems, Tucson, AZ), anti-
CD68 (1:500; Dako), and anti-CD8 (1:500; Ventana
Medical Systems, Tucson, AZ) antibodies. Total CD20+,
CD3+, CD4+, and CD8+ cells present in each slide
(one section per patient, N = 7 patients with liquefac-
tive necrosis strokes) were counted using a Motic
BA410 light microscope coupled with a MoticamPro
282A camera (Motic Images Plus 2.0 software) and a
10× objective, and divided by the area of tissue sam-
ple present on the slide to obtain the number of posi-
tivity stained cells per cm2.
Mouse immunohistochemistry
Frozen coronal sections (40 μm) were taken through the
entire brain using a Microm HM 450 sliding microtome
(Thermo Fisher Scientific, Walthman, MA). Primary
antibodies included anti-B220 (biotinylated, 1:500; BD
Biosciences, Franklin Lakes, NJ), anti-CD68 (1:1000;
AbD Serotec, Raleigh, NC), and anti-CD3e (the ε chain of
the T cell receptor associated CD3 complex, 1:500; BD
Biosciences). Briefly, free floating sections were immuno-
labeled with antibodies in conjuction with ABC Vector
Elite and 3,3’-diaminobenzidine kits for visualization.
B220+ and CD3e + cells were counted using the NIH
Image J (Media Cybernetics, Rockville, MD) cell count
function in the stroke core in 2 sections (bregma −
0.46 mm and −1.94 mm) per mouse, and 3 non-
overlapping fields (112 μm× 85 μm using a 20×
objective). Due to the denseness and intensity of CD68
immunoreactivity within each lesion, CD68 was quanti-
fied by measuring the percent area occupied by CD68
(n = 5–8 mice per group for CD3e-immunostaining,
Fig. 1 Staging of human brain tissue. a Infarcts and equivalent areas of brain from controls, were dissected and cut into two pieces. Each piece
was allocated for histological H&E staining and staging, or multiplex immunoassay. b Representative images of staging criteria. (i) Normal control
tissue, (ii) acute infarct with eosinophilic neurons clearly distinguishable. Some neuronal nuclei also display evidence of pyknosis and karyorrhexis
(arrows). (iii) Lesion at the stage of liquefactive necrosis, demonstrated by the presence of foamy macrophages. (iv) Lesion at the stage of
cystic encephalomalacia, evidenced by the presence of reactive astrocytes (an example is shown in the box) and a network of glial fibers.
Scale bar, 50 μm
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n = 4–12 mice per group for B220-immunostaining, and
n = 4–7 mice per group for CD68-immunostaining).
Flow cytometry
Stroke lesions from brains harvested 7 weeks following
stroke were dissected and combined for each mouse
strain (n = 9 lesions pooled from C57BL/6 mice, and n =
6 lesions pooled from BALB/c mice) to ensure sufficient
number of cells. To isolate immune cells, the pooled le-
sions were incubated in 3 % FBS/DMEM, followed by
dissociation of cells in ACK lysing buffer (Thermo Fisher
Scientific). Re-suspended cells were treated with 1 μM
ionomycin (Thermo Fisher Scientific), 50 ng/ml phorbol
12-myristate 13-acetate (Thermo Fisher Scientific), and
1 μl/ml GolgiPlug (BD Biosciences) for 4 h. Cells were
then re-suspended in Fixation/Permeabilization Buffer
(R&D Systems, Minneapolis, MN), after which 10 μl of
each antibody (except for 1 μl each of IL-17-Alexa Fluor
700, T-bet-PE, CD4-Pacific Blue, and FoxP3-Alexa Fluor
700), or corresponding isotype control antibody, was
added. Antibodies included: IFN-γ-CFS, (R&D Systems,
Minneapolis, MN), IL-12 Rβ2-APC (R&D Systems), T-
bet-PE (eBioscience, San Diego, CA), CD4-Pacific Blue
(BioLegend, San Diego, CA), IL-17-Alexa Fluor 700
(BioLegend, San Diego, CA), IL-4 R-CFS (R&D Systems),
STAT6-APC, (R&D Systems), IL-5-PE (R&D Systems),
CD4-Pacific Blue, and FoxP3-Alexa Fluor 700, (R&D
Systems). Cells were incubated for 45 min. They were
then analyzed using a FACScan flow cytometer (BD Bio-
sciences), and quantified using FlowJo software (Tree
Star, Ashland, OR). Gating strategy: Cells were gated by
forward scatter and side scatter to identify lymphocytes,
using lymphocytes isolated from the spleen as a positive
control. They were then gated on CD4+ expression.
Multiplex immunoassay
Frozen tissue from each human (n = 5–23 patients per
group; see Table 1 for exact n size per group) and mouse
(n = 5–10 mice per group; see Table 2 for exact n size
per group) cohort were homogenized in ice-cold phos-
phate buffered saline lysis solution containing 1 %
triton-X and 0.1 % sodium deoxycholate, complete with
Protease Inhibitor Cocktail (Sigma-Aldrich, Saint Louis,
MO) and Phosphatase Inhibitor Cocktail 2 (Sigma-Al-
drich) at a ratio of 1:100. Following centrifugation, the
total protein concentration of the supernatant was mea-
sured using a Direct Detect Infrared Spectrometer. Cyto-
kines and chemokines were then detected and quantified
Table 2 Number of mice used for cytokine and chemokine profile data
C57BL/6 mice (n = 90) BALB/c mice (n = 62)
Time-point Experimental group Age (months) n Time-point Experimental group Age (months) n
24 h Sham male mice 3 6 24 h Sham male mice 3 6
18 – 18 –
1 Stroke male mice 3 6 1 Stroke male mice 3 8
18 18 –
2 Strokes male mice 3 6 2 Strokes male mice 3 9
18 – 18 –
Week 1 Sham male mice 3 6 Week 1 Sham male mice 3 5
18 – 18 –
1 Stroke male mice 3 8 1 Stroke male mice 3 6
18 – 18 –
2 Strokes male mice 3 7 2 Strokes male mice 3 8
18 – 18 –
Week 7 Sham male mice 3 10 Week 7 Sham male mice 3 6
18 5 18 –
1 Stroke male mice 3 12 1 Stroke male mice 3 7
18 8 18 –
2 Strokes male mice 3 5 2 Strokes male mice 3 7
18 – 18 –
Sham female mice 3 5
18 –
1 Stroke female mice 3 6
Total number of mice, n = 152
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by multiplex immunoassays. Human high sensitivity and
mouse multiplex magnetic bead kits were purchased
from EMD Millipore (Billerica, MA) and used according
to the manufacturer’s recommendations. Each lysate
sample, standard, and quality control was measured in
duplicate. Plates were read using a MAGPIX instrument
(Luminex, Austin, TX), and results were analyzed using
MILLIPLEX Analyst 5.1 software (EMD Millipore). For
those analytes that were below the lower limit of detection,
the lower limit of detection values were used for data ana-
lysis. Concentrations of cytokines and chemokines were
normalized to concentrations of total protein in lysates.
Statistical analysis
For immunohistochemistry, blinding was not possible
because of the stroke lesion being clearly visible in
stroke patients versus normal control patients, as well as
stroke versus sham mouse groups. However, multiplex
immunoassay analyses were performed with blinding to
the stage of human strokes, as well as the ages, strains,
time-points, and one versus two strokes in mice. Data
are expressed as mean ± SEM. Statistical analyses were
performed with Prism 6.0 software (GraphPad, San
Diego, CA), with the level of significance set at p < 0.05.
Mouse immunohistochemistry data were analyzed using
a two-way ANOVA, followed by post-hoc Tukey’s mul-
tiple comparison testing (Fig. 5e), or two-tailed unpaired
t-test (Fig. 7c). Differences in cytokine and chemokine
concentrations between experimental groups (e.g., nor-
mal control versus acute stroke patients, or sham versus
stroke mice) were analyzed by Student’s t-test both with
and without correction for multiple comparisons using
the Holm-Sidak method. Both the uncorrected and cor-
rected statistics are provided in order to impart add-
itional information with regard to Type I error from this
dataset. Due to the multiple hypotheses tests, the uncor-
rected data may include differences that are false posi-
tives. The corrected data may exclude legitimate
differences because of the small sample size. The ration-
ale for providing the uncorrected data is to facilitate
cross-referencing the human and mouse data for future
studies. Differences that were significant without correc-
tion for multiple comparisons are denoted in the graphs
by asterisks. Differences that were significant with cor-
rection for multiple comparisons are referenced in the
Results section and denoted with red text in the graphs
(Figs. 2 and 3). To test for significant correlation in over-
all cytokine and chemokine profiles between experimen-
tal groups that include all 25 analytes (e.g., C57BL/6
mice at the 24 h time-point versus BALB/c mice at the
24 h time-point, or human acute stroke patients versus
C57BL/6 mice at the 24 h time-point), R squared and P
values were calculated using Prism 6.0 (Figs. 4 and 6).
To look for significant differences in individual cytokines
and chemokines between experimental groups that failed
to correlate, datasets were analyzed by two-way ANOVA
corrected for multiple comparisons using Sidak’s mul-
tiple comparisons test. These differences are provided in
Table 4. Two-way ANOVA was also used to look for
mean differences in the cytokine and chemokine re-
sponse to stroke in 3-month old versus 18-month old
mice, and between a first and second stroke. This was
followed by Sidak’s multiple comparisons test to look for
significant differences in individual cytokines and che-
mokines between these experimental groups (Figs. 7 and
8).
Results
Histopathological staging of the human tissue
Fresh frozen brain tissue from acute and chronic stroke
infarcts, and age-matched control brain tissue, was re-
quested from the Brain and Body Donation Program at
the Banner Sun Health Research Institute, the Human
Brain and Spinal Fluid Resource Center at the University
of California, Los Angeles, and the University of Miami
Brain Endowment Bank. This resulted in the acquisition
of tissue samples from 55 post-mortem brains; 33 sam-
ples came from patients with a clinical and neuropatho-
logical diagnosis of either acute or chronic stroke, and
23 samples came from age-matched control patients.
The autolysis cut-off time for this study was 24 h, and
the average autolysis time for each group ranged from
5.3 to 11.7 h (see Table 1 for patient information). Sam-
ples were dissected into two halves, one half was used
for H&E staining and immunostaining, and the other
half was used to generate lysates for multiplex immuno-
assays (Fig. 1a).
Due to a lack of clinical data to indicate the inter-
val between stroke and death for many of the pa-
tients, and thus the age of the infarcts, samples were
staged into three easily distinguishable categories that
represent distinct phases of infarct resolution in the
brain. Staging was performed by cross-referencing
clinical data supplied by the tissue banks with H&E
histopathology. The staging categories were (i) normal
control tissue, (ii) acute lesions, (iii) lesions at the
stage of liquefactive necrosis, and (iv) lesions at the
stage of cystic encephalomalacia, the final stage of in-
farct resolution.
To be classified as normal control tissue, tissue had to
appear homogenous and organized with typical-looking
nuclei. A representative image of an H&E stain of nor-
mal control brain tissue is shown in Fig. 1b, panel (i). To
be classified as a stroke lesion at the acute stage of in-
farction (i.e., hours old) samples met our criteria if we
could confirm the presence of eosinophilic degenerating
neurons, with an angular shape, vacuolation in the cyto-
plasm, and a shrunken darkly stained pyknotic nucleus
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[16]. A representative image of an H&E stain of a stroke
lesion at the acute stage of infarction is shown in Fig. 1b,
panel (ii). Samples were classified as at the stage of li-
quefactive necrosis (i.e. weeks to months old) if they
were principally comprised of foamy macrophages, as
shown in panel (iii) of Fig. 1b, and surrounded by an
astroglial scar (not shown in the image). Finally, as seen
in panel (iv) of Fig. 1b, lesions were classified as at the
stage of cystic encephalomalacia (months to years old) if
the infarct had been predominantly resorbed, leaving
empty spaces and a dense network of glial processes and
blood vessels.
Controlling for autolysis
Autolysis causes protein degradation, but how rapidly
this affects measurement of cytokine and chemokine
concentrations in the brain during the first 24 h post-
mortem is largely unknown [7, 24, 28]. Therefore, fol-
lowing histological staging, lysates prepared from the
control tissue were used for multiplex immunoassay to
evaluate whether there was a correlation between autoly-
sis time and cytokine and chemokine concentrations in
the cohort of control tissue. We performed this analysis
on control tissue to avoid the confounding impact of
stroke. A significant positive or negative correlation
Fig. 2 Cytokine and chemokine levels in human infarcts at the stages of acute stroke, liquefactive necrosis, and cystic encephalomalacia. Graphs
show the levels of 25 cytokines and chemokines in a acute infarcts (n = 5), b infarcts at the stage of liquefactive necrosis (n = 18), and c infarcts at
the stage of cystic encephalomalacia (n = 9). Data is presented as a fold-change compared to equivalent brain regions from control patients. Data
represent mean ± SEM. *p< 0.05 versus controls by Student’s t-test when uncorrected for multiple comparisons. Red indicates cytokines and chemokines
that were significantly different when corrected for multiple comparisons
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between autolysis time and cytokine and chemokine
concentration would indicate that protein degradation is
a confounding factor for the measurement of cytokine
and chemokine concentrations in the brain by multiplex
immunoassay in the first 24 h post-mortem. However, as
shown in Table 3 there was no correlation between
autolysis time and any cytokine and chemokine con-
centration in the brain. For this validation we in-
cluded fractalkine, which unlike many of the other
cytokines and chemokines, is highly expressed even at
basal levels in healthy brain tissue [35].
Cytokine and chemokine levels in human stroke infarcts
at the stages of acute stroke, liquefactive necrosis, and
cystic encephalomalacia
Lysates prepared from each sample were then used for
multiplex immunoassays to determine what cytokines
and chemokines are present in the human brain at the
acute stage of stroke, as well as at the later stages of li-
quefactive necrosis and cystic encephalomalacia. In hu-
man acute infarcts, we noted increased levels of 19 out
of 25 cytokines and chemokines compared to control
tissue (Fig. 2a): GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-4,
IL-6, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, IP-10, IL-8,
MCP-1, MIP-1α, MIP-1β, RANTES, and TNFα. If cor-
rected for multiple comparisons, there were significantly
higher levels of IL-1α, IL-2, IL-4, IL-6, IL-10, IL-12
(p70), IL-15, IL-17, IP-10, IL-8, MCP-1, MIP-1α, MIP-
1β, RANTES, and TNFα.
The levels of most of these cytokines and chemokines
were substantially decreased by 10–100 fold in the in-
farcts at the stage of liquefactive necrosis. Despite this
resolution, several cytokines and chemokines remained
elevated compared to control tissue: IL-6, IL-12 (p70),
IL-8, and MCP-1 (Fig. 2b). If corrected for multiple
comparisons, there were significantly higher levels of IP-
10, MIP-1α, and MIP-1β.
Levels of several cytokines and chemokines were also
higher than in controls in infarcts at the stage of cystic
encephalomalacia: G-CSF, IFNγ, IL-6, IL-7, IL-10, IL-15,
IP-10, IL-8, MCP-1, and RANTES (Fig. 2c). If corrected
for multiple comparisons, there were significantly higher
levels of G-CSF, IL-7, IL-10, IL-15, IP-10, and MCP-1.
Surprisingly, levels of several cytokines and chemokines
Fig. 3 Cytokine and chemokine levels in C57BL/6 and BALB/c mouse infarcts at the stages of acute stroke (24 h), sub-acute stroke (1 week), and
liquefactive necrosis (7 weeks). Graphs show the levels of 25 cytokines and chemokines in a acute infarcts, b sub-acute infarcts, and c infarcts at
the stage of liquefactive necrosis (n’s provided in Table 2). Data is presented as a fold-change compared to equivalent cortex dissected from sham
mice from each strain. Data represent mean ± SEM. *p < 0.05 versus sham by Student’s t-test when uncorrected for multiple comparisons. Red
indicates cytokines and chemokines that are significantly different when corrected for multiple comparisons
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were decreased compared to control tissue: IL-1β, IL-2,
IL-5 IL-12 (p70), IL-13, IL-17 and MIP-1β. If corrected
for multiple comparisons there were significantly lower
levels of IL-2 and IL-12 (p70).
These data demonstrate that there is substantial reso-
lution of the inflammatory response to stroke between
the acute time period and the stages of liquefactive ne-
crosis and cystic encephalomalacia. However, they also
suggest that many pro-inflammatory cytokines and che-
mokines (IL-6, RANTES, IL-12 (p70), MCP-1, MIP-1α,
MIP-1β) [10, 38] remain chronically elevated at low
levels within infarcts resolving by liquefactive necrosis, a
process that proceeds for an unknown length of time in
the human brain following stroke.
Cytokine and chemokine levels in mouse infarcts at 24 h,
1 week, and 7 weeks following stroke
To reveal similarities and differences between mice and
humans, we cross-matched the human multiplex im-
munoassay data with immunoassay data from mice. We
used two popular inbred strains of mice, C57BL/6 and
BALB/c mice, to control for mouse strain-related differ-
ences in the inflammatory response to stroke. After in-
ducing strokes, mice were euthanized at three different
Fig. 4 Correlation of cytokine and chemokine levels in mouse and human acute infarcts, and infarcts at the stage of liquefactive necrosis. Data
from Figs. 2 and 3 have been replotted to provide a direct comparison of cytokine and chemokine levels in acute mouse and human infarcts (a,
b, and c), and human and mouse infarcts at the stage of liquefactive necrosis (d, e, and f). The specific cytokines and chemokines that are
significantly different between each strain, and different between humans and each strain are provided in Table 4. The solid lines depict the
correlation when all 25 cytokines and chemokines are taken into consideration for the calculation of the Pearson’s R values. The dotted lines
depict the correlation when the cytokines and chemokines that are significantly different between species by a two-way ANOVA corrected for
multiple comparisons are excluded from the calculation of the Pearson’s R values
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time-points: 24 h following stroke to model acute stroke
in humans, 1 week following stroke to model sub-acute
stroke in humans, and 7 weeks following stroke to
model infarcts at the stage of liquefactive necrosis in
humans. We were unable to model the stage of cystic
encephalomalacia because infarcts from mice euthanized
as late as 14 weeks following stroke were still at the
stage of liquefactive necrosis (data not shown).
As seen in Fig. 3a (left graph), there were increased
levels of the following cytokines and chemokines in the
lesion in C57BL/6 mice at 24 h post-stroke compared to
the equivalent cortical location from control sham mice:
G-CSF, GM-CSF, IL-5, IL-6, IL-12 (p70), IP-10, KC
(homologue to IL-8 in humans), MCP-1, MIP-1α, MIP-
1β, MIP-2A, RANTES, and TNFα. The level of IL-9 was
decreased in C57BL/6 mice at 24 h post-stroke
compared to sham mice. If corrected for multiple com-
parisons, there were significantly higher levels of MCP-1
and MIP-1β.
There was substantial overlap in the inflammatory re-
sponse to acute stroke in BALB/c mice compared to
C57BL/6 mice at 24 h post-stroke. In BALB/c mice there
was an increase in G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β,
IL-2, IL-4, IL-5, IL-7, IL-9, IL-10, IL-12 (p40), IL-12
(p70), IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1α,
MIP-1β, MIP-2A, RANTES, and TNFα in the lesion
compared to an equivalent area of cortex from sham
controls (Fig. 3a, right graph). If corrected for multiple
comparisons, there were significantly higher levels of G-
CSF, GM-CSF, IL-1α, IL-5, IL-7, IL-12 (p40), IL-15, IP-
10, KC, MCP-1, MIP-1α, MIP-1β, MIP-2A, and TNFα.
In C57BL/6 mice at 1 week post-stroke, despite sub-
stantial resolution, G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β,
IL-4, IL-5, IL-6, IL-10, IL-12 (p40), IL-12 (p70), IP-10,
KC, MCP-1, MIP-1α, MIP-1β, MIP-2A, RANTES, and
TNFα remained elevated in the infarct compared to the
equivalent area of cortex from sham mice (Fig. 3b, left
graph). If corrected for multiple comparisons, there were
significantly higher levels of IP-10 and RANTES com-
pared to sham mice. In BALB/c mice at 1 week post-
stroke G-CSF, IP-10, KC, MCP-1, MIP-1α, and MIP-1β
were increased, and levels of IL-1β, IL-10, and IL-13
were decreased compared to sham mice (Fig. 3b, right
graph). If corrected for multiple comparisons, there were
significantly higher levels of IP-10 and MIP-1β.
In C57BL/6 mice at 7 weeks post-stroke there were in-
creased levels of G-CSF, GM-CSF, IFNγ, IL-1α, IL-5, IL-
6, IL-12 (p40), IL-12 (p70), IP-10, KC, MCP-1, MIP-1α,
MIP-1β, MIP-2A, RANTES, and TNFα within the in-
farct compared to the equivalent area of cortex from
sham mice (Fig. 3c, left graph). If corrected for multiple
comparisons, there were significantly higher levels of G-
CSF, GM-CSF, IL-5, IL-6, IL-12 (p70), IP-10, KC, MCP-
1, MIP-1α, MIP-1β, MIP-2A, RANTES, and TNFα com-
pared to sham mice.
In BALB/c mice at 7 weeks post-stroke, levels of G-
CSF, IL-2, IL-6, IL-17, IP-10, MCP-1, and RANTES were
increased, and levels of GM-CSF, IFNγ, IL-10 were de-
creased compared to sham mice (Fig. 3c, right graph). If
corrected for multiple comparisons there were signifi-
cantly higher levels of IL-17 and MCP-1, and a signifi-
cantly lower level of IFNγ.
As seen by comparing Figs. 2a and 3a, the cytokines
and chemokines that were uniformly increased in the
acute infarcts from C57BL/6 mice, BALB/c mice, and
humans were GM-CSF, IL12 (p70), IP-10, KC/IL-8,
MCP-1, MIP-1α, MIP-1β, RANTES, and TNFα. This
shared expression pattern of cytokines and chemokines
indicates that there is substantial overlap in the inflam-
matory response to stroke in acute infarcts between
Table 3 There is no correlation between autolysis time and








GM-CSF 0.0870 0.7314 ns
Fractalkine −0.0675 0.7901 ns
IFNγ −0.2062 0.4116 ns
IL-10 0.2294 0.3597 ns
MIP-3α 0.1972 0.4328 ns
IL-12 (p70) 0.1332 0.5983 ns
IL-13 0.3367 0.1718 ns
IL-17A 0.0125 0.9608 ns
IL-1α 0.0285 0.9107 ns
IL-2 0.0435 0.8639 ns
IL-21 0.0321 0.8995 ns
IL-4 −0.0020 0.9939 ns
IL-23 −0.0045 0.9857 ns
IL-5 0.0172 0.9460 ns
IL-6 0.3862 0.1134 ns
IL-7 0.1697 0.5007 ns
IL-8 −0.1325 0.6001 ns
MIP-1α 0.0968 0.7025 ns
MIP-1β −0.0552 0.8278 ns
TNFα −0.1334 0.5976 ns
G-CSF 0.0057 0.9822 ns
IL-15 −0.1552 0.5386 ns
IL-1α −0.1725 0.5080 ns
IL-9 0.0256 0.9198 ns
IP-10 −0.2842 0.2531 ns
MCP-1 0.1016 0.6882 ns
RANTES 0.1229 0.6269 ns
ns nonsignificant based on significance set at p < 0.05
Nguyen et al. Acta Neuropathologica Communications  (2016) 4:100 Page 10 of 20
humans and these two mouse strains at 24 h post-
stroke.
Correlation of the acute inflammatory response to stroke
in mice and humans
The preceding data was then analyzed to determine the
degree of correlation between C57BL/6 mice and BALB/
c mice to identify strain similarities and differences, and
the degree of correlation between each mouse strain and
humans to identify conserved cytokine and chemokine
expressions.
We found a significant correlation in the acute cyto-
kine and chemokine response to stroke between C57BL/
6 and BALB/c mice at 24 h post-stroke (R2 = 0.9848, p <
0.0001; Fig. 4a), and at 1 week post-stroke (R2 = 0.8930,
p < 0.0001; data not shown). These data indicate that
with regard to the cytokines and chemokines measured
in this study, inflammation during acute and sub-acute
stroke is not significantly different in C57BL/6 and
BALB/c mice.
However, there was a lack of correlation between
C57BL/6 mice and humans at the acute stage of stroke
(R2 = 0.0021; p = 0.8357, Fig. 4b, solid line), or between
BALB/c mice and humans at the acute stage of stroke
(R2 = 0.0039; p = 0.7782, Fig. 4c, solid line). When we
performed a two-way ANOVA that was corrected for
multiple comparisons, we found that G-CSF, IL-6, and
KC/IL-8 were significantly different between C57BL/6
mice and humans, and G-CSF and IL-6 were signifi-
cantly different between BALB/c mice and humans at
this acute stage of stroke (Table 4).
The acute cytokine and chemokine response to stroke
in C57BL/6 mice still failed to show a significant correl-
ation with humans when G-CSF, IL-6, and KC/IL-8 were
excluded from the calculation of the R2 value (R2 =
0.0254, p = 0.5018; Fig. 4b, dotted line). However, the
acute cytokine and chemokine response to stroke in
BALB/c mice did correlate with humans when G-CSF
and IL-6 were excluded from the R2 calculation (R2 =
0.1920, p = 0.0470; Fig. 4c, dotted line).
These data suggest that there may be a differential
regulation of G-CSF and IL-6 between humans and
these two mouse strains, and that there is a stronger
conservation of the acute cytokine and chemokine re-
sponse to stroke between BALB/c mice and humans as
compared to C57BL/6 mice and humans.
Correlation of the chronic inflammatory response to
stroke in mice and humans
Along with overlap in the acute inflammatory response
to stroke, there was also overlap in the inflammatory re-
sponse to stroke in infarcts at the stage of liquefactive
necrosis. IL-6 and MCP-1 levels were increased in areas
of liquefactive necrosis in humans and both strains of
mice (Figs. 2b and 3c).
With regard to correlation, we discovered a significant
correlation in the cytokine and chemokine levels present
in the infarcts dissected from C57BL/6 mice and BALB/
c mice at 7 weeks following stroke (R2 = 0.8929, p <
0.0001; Fig. 4d). However, a two-way ANOVA corrected
for multiple comparisons revealed that despite this cor-
relation, there were still significant differences in the
levels of G-CSF, IL-17, IP-10, KC, MCP-1, MIP-1β, and
RANTES between these two strains (Table 4). These
data indicate that despite a significant correlation, there
is still a divergence in the chronic inflammatory re-
sponse to stroke in C57BL/6 and BALB/c mice at the
stage of liquefactive necrosis.
At the stage of liquefactive necrosis, the cytokine and
chemokine response to stroke failed to correlate between
C57BL/6 mice and humans (R2 = 0.0468, p = 0.3215,
Fig. 4e, solid line). Two-way ANOVA corrected for mul-
tiple comparisons showed significant differences in the
levels of G-CSF and MIP-1α between these two groups
(Table 4). When G-CSF and MIP-1α were excluded from
the calculation of the R2 value, the cytokine and chemo-
kine response to stroke at the stage of liquefactive ne-
crosis correlated between C57BL/6 mice and humans
(R2 = 0.7818, p < 0.0001; Fig. 4e, dotted line). This sug-
gests that although there is differential regulation of G-
CSF and MIP-1α between C57BL/6 mice and humans at
the stage of liquefactive necrosis following stroke, there
is an otherwise strong correlation if these differences are
taken into account.
At the stage of liquefactive necrosis, the cytokine and
chemokine response to stroke also failed to correlate be-
tween BALB/c mice and humans (R2 = 0.1500, p =
0.0679; Fig. 4f, solid line). By a two-way ANOVA cor-
rected for multiple comparisons, there was a significant
difference in the levels of G-CSF between these two
groups (Table 4). However, after G-CSF was excluded
from the R2 calculation, the cytokine and chemokine
Table 4 Cytokines and chemokines that are significantly
different between strains and species
Comparison Cytokines and chemokines that are
significantly different by a two-way
ANOVA corrected for multiple
comparisons
Human acute vs C57BL/6 24 h
stroke
G-CSF, IL-6, KC/IL-8
Human acute vs BALB/c 24 h
stroke
G-CSF, IL-6
C57BL/6 vs BALB/c week 7 stroke G-CSF, IL-17, IP-10, KC, MCP-1,
MIP-1β, RANTES
Human liquefactive necrosis vs
C57BL/6 week 7 stroke
G-CSF, MIP-1α
Human liquefactive necrosis vs
BALB/c week 7 stroke
G-CSF
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response to stroke at the stage of liquefactive necrosis
correlated between BALB/c mice and humans (R2 =
0.7265, p < 0.0001; Fig. 4f, dotted line). This suggests that
similar to C57BL/6 mice, there is also differential regula-
tion of G-CSF between BALB/c mice and humans at the
stage of liquefactive necrosis, and if this difference is
taken into account, then there is an otherwise strong
correlation between BALB/c mice and humans.
Composition of immune cell infiltrates in human and
mouse infarcts at the stage of liquefactive necrosis
To further investigate heterogeneity in the inflamma-
tory response to liquefactive necrosis, we next evalu-
ated what immune cells are present in human and
mouse infarcts during this stage of infarct resolution.
Tissue underwent immunostaining for macrophages/
microglia, T-lymphocytes, and B-lymphocytes. In both
species, and each strain of mouse, CD68+ macro-
phages were uniformly present within the infarcts
(Fig. 5a, c, d, and e). There were also T and B cells
present within the infarcts in both strains of mice, and
in most humans. However, in humans and each strain
of mouse, there was a substantial difference in the ex-
tent of T-lymphocyte (CD4+ and CD8+ cells in
humans and CD3+ cells in mice), and B-lymphocyte
(CD20+ cells in humans and B220+ cells in mice) in-
filtration in the infarct (Fig. 5b and e). C57BL/6 mice
had significantly greater numbers of T and B cells
within the infarct than the BALB/c mice, and substan-
tially more than in humans. In mice, this was due to a
difference in delayed infiltration of T and B cells be-
cause there was no difference in the number of T and
B cells present within lesions analyzed 1 week follow-
ing stroke (Fig. 5e). The number of T and B cells
present in the infarcts was more heterogeneous in the
human patients than either inbred mouse strain, with
some humans showing no evidence of B cells within
the infarct (Fig. 5b and e).
Next, we compared the phenotype of the T-lymphocytes
present in the mouse infarcts by flow cytometry with the
goal of determining if there is heterogeneity not only in
the magnitude of the adaptive immune response to stroke
during infarct resolution, but also in the polarization of
the adaptive immune response. We discovered that at
7 weeks post-stroke, the T cells present in the infarct in
C57BL/6 mice had an increased polarization towards a
Th1 phenotype when compared to BALB/c mice. This
was evidenced by an increased prevalence of CD4+ cells
in the infarct in C57BL/6 mice that were also positive for
T-bet, a Th1 transcription factor, and IFN-γ, a key Th1
cytokine (Fig. 5f and j). In contrast, the T cells present in
the infarct in BALB/c mice had an increased polarization
towards a Th2 phenotype. This was evidenced by an in-
creased prevalence of CD4+ cells in the infarct in BALB/c
mice that were also positive for STAT6, a Th2 transcrip-
tion factor, and IL-4, a key Th2 cytokine (Fig. 5g and j).
The disparate polarization of T cells towards a Th1 or Th2
phenotype within the infarct in the different strains sup-
ports that inflammation may follow a different trajectory
in different individuals during the stage of liquefactive
necrosis.
In both strains, we found few CD4+ cells that were
also IL-17+ within the infarcts (Fig. 5h and j), and no
CD4+ cells that were also Foxp3+ (Fig. 5i and j). This in-
dicates that in both strains, at the stage of liquefactive
necrosis, there are few Th17 and regulatory T cells
(Treg) present within the infarct.
Correlation of the chronic inflammatory response to
stroke in males and females
Biological sex is known to play a role in stroke inci-
dence, prevalence, and severity [19], however no studies
have investigated if the chronic inflammatory response
to stroke is sexually dimorphic. Therefore, we investi-
gated how well the chronic inflammatory response to
stroke correlates in males and females in both C57BL/6
mice and in humans. We found a significant correlation
in the cytokine and chemokine response to stroke be-
tween male and female C57BL/6 mice at 7 weeks post-
stroke (R2 = 0.6199, p < 0.0001; Fig. 6a), and between
male and female human infarcts at the stage of liquefac-
tive necrosis (R2 = 0.1724, p < 0.0488; Fig. 6b). These data
indicate that with regard to the cytokines and chemo-
kines measured in this study, sexual dimorphism does
not prevent the chronic inflammatory response to stroke
in male and female C57BL/6 mice, and male and female
humans, from correlating.
Age moderately attenuates the chronic T cell response to
stroke in 18-month old C57BL/6 mice
The human post-mortem tissue used in this study came
from elderly individuals with an average age of 79.9 years
and there is evidence to suggest that the inflammatory
response to stroke is attenuated in aged mice [42]. To
evaluate if age may explain why there was substantially
less adaptive immune cell infiltration in the human
stroke lesions at the stage of liquefactive necrosis than in
the lesions from the 3-month old C57BL/6 mice, we de-
termined whether the inflammatory response to stroke
in C57BL/6 mice declines with age. To accomplish this
goal, 18-month old C57BL/6 mice underwent DH stroke
and were sacrificed 7 weeks later. As seen in Fig. 7a, the
18-month old C57BL/6 mice shared a similar cytokine
and chemokine profile in the infarct compared to the 3-
month old mice. There was no significant difference in
the mean cytokine and chemokine levels by two-way
ANOVA. However, there were differences in the levels
of several cytokines and chemokines when corrected for
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Fig. 5 Immune cell composition in infarcts at the stage of liquefactive necrosis in humans and mice. a Representative images of CD3+ T-
lymphocyte, CD20+ B-lymphocyte, and CD68+ macrophage/microglia infiltration in human infarcts at the stage of liquefactive necrosis. Scale bars,
10 μm (human, CD3 and CD20 images) and 30 μm (human, CD68 image). b Quantification of CD4+ and CD8+ T-lymphocyte, and CD20+ B-
lymphocyte infiltration into the infarcts. c Representative images of CD3+ T-lymphocytes, B220+ B-lymphocytes, and CD68+ macrophages/micro-
glia in the infarcts of C57BL/6 and BALB/c mice at 7 weeks post-stroke. Scale bar,100 μm. d Higher magnification images of CD68+ macrophages/
microglia in the infarct to reveal individual cells. Scale bar, 25 μm. e Quantification of CD3+ T-lymphocyte infiltration, B220+ B-lymphocyte
infiltration, and CD68 immunostaining in mouse infarcts. ****p < 0.0001 compared to week 1, +++ p < 0.001 compared to BALB/c, ++++ p <
0.0001 compared to BALB/c. f Flow cytometry on cells gated by CD4, using markers of Th1 cells (T-bet and IFNγ), demonstrates that at 7 weeks
post-stroke, the CD4+ T cell response in the infarct in C57BL/6 mice is more polarized towards a Th1 response than in BALB/c mice. g Flow cy-
tometry on cells gated by CD4, using markers of Th2 cells (STAT6 and IL-4), demonstrates that at 7 weeks post-stroke, the T cell response in the
infarct in BALB/c mice is more polarized towards a Th2 response than in C57BL/6 mice. h There were few CD4+ IL-17+ cells detected in the
infarct of both strains. i There were no CD4+ Foxp3 cells detected in the infarct in either strain. j Table showing the % CD4 lymphocytes positive
for each marker
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multiple comparisons; KC was decreased, and RANTES
was increased.
With regard to immune cell infiltration, there was no
difference in B cell infiltration, but there was a signifi-
cant reduction in T cell infiltration into the area of lique-
factive necrosis in the aged mice. Nevertheless, even
with this reduced infiltration the number of T cells
within the infarct in the aged mice was significantly
greater than the number of T cells present within the in-
farcts from the human samples (data not shown). Thus,
although we detected a moderate attenuation of the in-
flammatory response in the aged mice with regard to T
cell infiltration, it was not sufficient to explain why the
inflammatory response to liquefactive necrosis is dispar-
ate in C57BL/6 mice and humans.
Prior stroke exacerbates the inflammatory response to
stroke in mice
Presently, little is known about the interaction of mul-
tiple sequential ischemic strokes on the inflammatory
response to stroke in the human brain, despite the fact
that 25 % of the approximately 800,000 strokes that
occur in the United States every year are recurrent
strokes [32]. There is substantial evidence from animal
models that demonstrates that a non-injurious mild
ischemic insult can confer transient preconditioning
protection against a second insult [20, 45]. On the con-
trary, evidence also suggests that once a threshold of in-
jury has been reached, a mild ischemic stroke followed
by a second stroke can exacerbate brain damage [6].
Therefore, because many of the human samples we ana-
lyzed came from individuals that had suffered multiple
strokes, we sought to determine (i) the impact of mul-
tiple strokes on the brain’s immune response, and (ii)
whether the impact of multiple strokes differs in mouse
strains.
C57BL/6 and BALB/c mice underwent DH or
DMCAO stroke respectively, followed by an equivalent
second stroke on the contralateral hemisphere 3 weeks
later. After 24 h, 1 week, and 7 weeks following the sec-
ond stroke, the second stroke lesions were dissected and
multiplex immunoassays were performed.
As seen in Fig. 8a, in the C57BL/6 mice at 24 h follow-
ing stroke, there was a significant difference in the mean
cytokine and chemokine levels of the second stroke
compared to the first stroke by two-way ANOVA (p =
0.0170). With correction for multiple comparisons, there
was significantly more G-CSF and IL-6 present in the
second infarct. In BALB/c mice (Fig. 8b), there was no
significant difference in the overall cytokine and chemo-
kine profile for one stroke versus two strokes at 24 h by
two-way ANOVA (p = 0.3327).
At 1 week post-stroke in C57BL/6 mice, there was no
significant difference in the overall cytokine and chemo-
kine profile between the first and second stroke by two-
way ANOVA (p = 0.8209) (Fig. 8c). Likewise, at 1 week
post-stroke, there was no significant difference in the
overall cytokine and chemokine profile by two-way
ANOVA between the first and second stroke in BALB/c
mice (Fig. 8d) (p = 0.6196).
However, at 7 weeks post-stroke in C57BL/6 mice, there
was a significant difference in the overall cytokine and
chemokine profile between the first and second stroke by
two-way ANOVA (p < 0.0156; Fig. 8e). This difference in
one versus two strokes is highlighted by a significant in-
crease in the level of RANTES when corrected for mul-
tiple comparisons. Similarly, in BALB/c mice, there was
also a significant difference in the overall cytokine and
chemokine profile between the first and second stroke
by two-way ANOVA (p < 0.0001; Fig. 8f ). However,
Fig. 6 Impact of sex on the chronic inflammatory response to stroke
in C57BL/6 mice and humans. a Comparison of cytokine and
chemokine levels in infarcts at the stage of liquefactive necrosis
from male and female C57BL/6 mice reveals that there is a
significant correlation between each sex. b Comparison of cytokine
and chemokine levels in infarcts at the stage of liquefactive necrosis
from male and female stroke patients reveals that there is also a
significant correlation between each sex in humans
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there was a significant increase in the levels of IL-4
and MIP-1α in this strain when corrected for multiple
comparisons.
Together, these data indicate that although the acute
and chronic inflammatory response to a second stroke is
remarkably consistent, there does appear to be a mild
but significant shift towards a more pro-inflammatory
chronic response to a recurrent stroke, with the charac-
teristics of the shift being strain dependent.
Discussion
Despite decades of stroke research, the cytokine re-
sponse to stroke in the healing human brain is largely
uncharacterized. One of the reasons for the scarcity of
this kind of published data is the challenge to obtain tis-
sue from individuals that have died at multiple synchro-
nized stages of infarct resolution following stroke, and
died without a confounding neurological co-morbidity
such as Alzheimer’s disease. Due to this limitation, we
were only able to accurately stage and analyze tissue
from 33 patients with a clinical and neuropathological
diagnosis of either acute or chronic stroke. In light of
this small cohort there are likely to be type I errors in
the data analyzed without correction for multiple
comparisons, and the data analyzed with correction for
multiple comparisons may exclude legitimate differ-
ences. To enable future studies to differentiate signal
from noise, and to compensate for this small cohort, we
present data analyzed by both statistical approaches. We
also performed a parallel analysis of the cytokine and
chemokine response to stroke in the healing mouse
brain. Overlap between the two species, in terms of
which cytokines and chemokines are increased and
decreased, are more likely to represent legitimate and
translatable findings with regard to the inflammatory
response to stroke in the human brain.
Fig. 7 Impact of age on the chronic inflammatory response to stroke in C57BL/6 mice. a Comparison of the levels of 25 cytokines and
chemokines in infarcts at the stage of liquefactive necrosis dissected from 3-month old and 18-month old C57BL/6 mice at 7 weeks post-stroke.
Data are expressed as a fold-change relative to age matched sham control values. Data represent mean ± SEM. There is no significant difference
in the overall cytokine and chemokine profile at the stage of liquefactive necrosis between 3-month old and 18-month old mice by two-way
ANOVA. Cytokines and chemokines that are significantly different between the 3-month old and 18-month old mice corrected for multiple com-
parisons are denoted by an asterisk (*p < 0.05 versus 3-month old mice). b Representative images of CD3+ T-lymphocytes, B220+ B-lymphocytes,
and CD68+ macrophages/microglia in the infarcts of 3-month old and 18-month old C57BL/6 mice at 7 weeks post-stroke. Scale bar, 50 μm. Red
dotted lines indicate locations of the glial scar in each image. c Quantification of CD3+ T-lymphocyte and B220+ B-lymphocyte infiltration into the
mouse infarcts
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A small sample size is not the only limitation of this
study. Autolysis is a significant challenge for multiplex
immunoassay investigations of human brain due to the
difficulty of obtaining post-mortem tissue rapidly. How-
ever, despite autolysis causing protein degradation, mul-
tiple studies have shown that many human brain
proteins are relatively stable with respect to post-
mortem intervals (PMI) of less than 24 h [7, 24, 28]. On
the other hand, multiple studies have also shown that
the abundance and integrity of proteins within the hu-
man brain can exhibit marked intercase variability due
to such factors as whether an individual died of a pro-
longed illness with progressive hypoxia, or died suddenly
of a cardiac arrhythmia [7, 24, 28]. These discrepancies
make comparisons between groups difficult because
there is likely to be large intra-group variability in these
parameters. These parameters cannot be easily con-
trolled for without conducting a rigorous prospective
study. However, we found no correlation between au-
tolysis time and cytokine and chemokine levels in the
cohort of human control tissue. Although this finding
does not definitively rule out the possibility that levels of
cytokines and chemokines measured in this study were
significantly altered by autolysis, it does provide add-
itional assurance of the validity of the measurements.
Furthermore, because autolysis time was kept to less
than 5 min for the mice used in this study, performing a
parallel analysis of the cytokine and chemokine response
to stroke in the human and mouse brain also mitigates
this limitation.
There are significant differences in the immune re-
sponse to stroke in different mouse strains with regard
to the frequency and distribution of different types of
immune cells such B-lymphocytes, neutrophils, mono-
cytes, and macrophages, and in the polarization of T cell
responses [4]. To control for these strain differences, we
Fig. 8 Impact of recurrent stroke on the acute, sub-acute and chronic inflammatory response to stroke in C57BL/6 and BALB/c mice. Graphs show
a comparison of the levels of 25 cytokines and chemokines in acute infarcts (a and b), sub-acute infarcts (c and d), and infarcts at the stage of li-
quefactive necrosis (e and f) dissected from a first or second stroke. In mice that underwent two stroke procedures, each stroke was separated by
3 weeks. Only the infarct at the site of the second stroke was compared to the infarct from mice that had undergone a single stroke procedure.
Data are expressed as a fold-change relative to values from mice that underwent a single sham surgery. Blue text denotes where there is a signifi-
cant difference in the overall cytokine and chemokine profile between the first and second stroke by two-way ANOVA. Cytokines and chemokines
that are significantly different between the first and second stroke, corrected for multiple comparisons, are denoted by an asterisk
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used both C57BL/6 and BALB/c mice. These two strains
are known to have significant differences in their im-
mune response and susceptibility to autoimmune dis-
eases. C57BL/6 mice represent a canonical Th1 mouse
strain, while BALB/c mice represent a canonical Th2
mouse strain [49].
With regard to which cytokines and chemokines are
increased in both humans and mice in acute stroke, we
found that GM-CSF, IL12 (p70), IP-10, KC/IL-8, MCP-1,
MIP-1α, MIP-1β, RANTES, and TNFα are significantly
higher in both species, and in both strains of mice com-
pared to non-stroked controls. The putative role and
functional relevance of each of these cytokines and che-
mokines is summarized in Table 5.
We also found that there was a significant correlation
between the global cytokine and chemokine profile to
acute stroke in each mouse strain. However, there was a
clear difference in the acute cytokine and chemokine re-
sponse to stroke in humans and mice in terms of the
regulation of G-CSF. G-CSF was robustly increased in
both C57BL/6 and BALB/c mice in acute stroke, but was
not increased in acute stroke in humans. G-CSF has re-
peatedly been shown to be neuroprotective in mouse
models of stroke, but recently failed a human clinical
trial [36, 39, 40]. The difference in the regulation of G-
CSF in the two species in response to stroke may also
mean that the neuroprotective role that G-CSF plays in
mice may be less relevant for humans.
With regard to sub-acute stroke, we found that there
is substantial resolution of the inflammatory response to
stroke in mice between 24 h and 1 week after stroke.
However, in the days following stroke the inflammatory
response in the brains of C57BL/6 and BALB/c mice be-
gins to diverge. These findings suggest that although the
initial response to stroke is very conserved, the reso-
lution of inflammation may follow a different path in dif-
ferent individuals. We did not look at the inflammatory
response to sub-acute stroke in humans because we
were unable to obtain sufficient tissue that met our sta-
ging criteria for this time-point. Once tissue becomes
available, we will investigate the inflammatory response
to sub-acute stroke in humans in a follow-up study.
With regard to chronic stroke, MCP-1 and IL-6 were
significantly elevated in both mice and humans in in-
farcts at the stage of liquefactive necrosis, and CD68+
microglia/macrophages were the predominant cell type.
In mice, this stage lasts for at least 14 weeks, and it is
unknown how long this stage lasts in humans, although
it may vary depending upon the size and location of the
infarct. Based on our unpublished observations in mice,
Table 5 Putative role(s) of cytokines and chemokines that are increased in both human and mouse stroke
Cytokine/
chemokine
Time-point Putative role Selected
references
GM-CSF Acute Hematopoietic growth factor that plays a neuroprotective and angiogenic role in animal models of stroke. [33, 47]
IL12 (p70) Acute Sub-unit of the pro-inflammatory cytokine IL-12. Produced by antigen presenting cells. Co-factor for the
polarization of T cells towards Th1 cell-mediated immunity. Role in animal models of stroke unknown.
[50]
IP10 Acute Pro-inflammatory chemokine for monocytes and Th1 cells. Role in animal models of stroke unknown. [41]
KC/IL-8 Acute KC and IL-8 are pro-inflammatory chemokine homologues that promote neutrophil recruitment to sites of tis-
sue damage. Targeting neutrophils has mixed effects in animal models of stroke. Neutrophil blockade has so
far failed to show therapeutic benefit at clinical trial.
[12]
MCP-1 Acute Chemokine for monocytes, hematogenous macrophages, neutrophils, memory T-lymphocytes and natural killer
cells. Increases infarct size in animal models of stroke. However, MCP-1/CCR2 signaling has also been shown to
reduce hemorrhagic transformation in animal models of stroke.
[21, 46]
MIP-1α Acute Chemokine for macrophages, monocytes and neutrophils. Ligand for CCR5. CCR5 deficient mice have
increased brain damage after ischemic stroke. However, mice lacking CCR5 in the periphery have reduced
brain damage after ischemic stroke. The role of MIP-1α in mediating these mixed results is unknown.
[44]
MIP-1β Acute Chemokine for macrophages, monocytes and neutrophils. Also a ligand for CCR5. The role of MIP-1β in mediat-
ing the mixed results of targeting CCR5 signaling following stroke is unknown.
[11, 44]
RANTES Acute Chemokine for multiple leukocyte subsets, including T cells. Also a ligand for CCR5. Evidence from animal
models suggests that RANTES is a primary mediator of cerebral inflammation, blood-brain barrier dysfunction,
and tissue damage following stroke
[48]
TNFα Acute Pleiotropic pro-inflammatory cytokine that can activate NF-kB signaling, MAPK signaling, and induction of
apoptosis in target cells. Both injurious and beneficial roles of TNFα have been demonstrated. Blockade of





Pro-inflammatory cytokine secreted by T cells and macrophages. An acute increase in IL-6 in the CNS is neuro-




Chemokine for monocytes, hematogenous macrophages, neutrophils, memory T-lymphocytes and natural killer
cells. Role in chronic stroke infarcts unknown. However, prolonged MCP-1 elevation correlates with poor infarct
resolution after spinal cord injury.
[18]
Nguyen et al. Acta Neuropathologica Communications  (2016) 4:100 Page 17 of 20
we hypothesize that it likely lasts for substantially longer
than 14 weeks even for very small infarcts. Both MCP-1
and IL-6 are associated with pro-inflammatory macro-
phages, which we interpret to mean that in both humans
and mice the macrophage response to stroke does not
resolve towards a reparative tissue remodeling pheno-
type as efficiently as the macrophage response to dam-
age in other tissues [15]. A similar chronic activation of
macrophages has been observed in the spinal cord fol-
lowing injury [18]. The putative role and functional rele-
vance of MCP-1 and IL-6 in infarcts at the stage of
liquefactive necrosis is also summarized in Table 5.
In this study, we did not evaluate polymorphonuclear
granulocyte infiltration in areas of liquefactive necrosis.
Although Enzmann and colleagues have shown the
presence of polymorphonuclear granulocytes within
cerebral vessels in infarcted human stroke tissue at
early time points, it remains to be determined
whether granulocytes are still present at the stage of
liquefactive necrosis, and if they have extravasated
into the infarct at this stage [13].
The overall cytokine and chemokine profile in areas of
liquefactive necrosis significantly correlated in each
strain of mouse, and in humans and mice when G-CSF
was excluded. However, there was heterogeneity in T-
and B-lymphocyte infiltration into the lesion in each
strain of mouse and in humans. In C57BL/6 mice, there
were substantially more adaptive immune cells in the le-
sion than in either BALB/c mice or humans, and the T
cells were more polarized towards a Th1 phenotype than
in BALB/c mice. These data are in line with previous
studies that have shown that C57BL/6 mice skew to-
wards Th1 inflammatory responses, while BALB/c mice
skew towards Th2 inflammatory responses [49].
The difference in the acute cytokine and chemokine
profile between mice and humans, and the difference
in the extent of chronic adaptive immune cell infiltra-
tion between C57BL/6 mice and humans, means that
caution should be taken when using mice, and a sin-
gle strain, to extrapolate the inflammatory response
to stroke in humans. The strain heterogeneity also
highlights the need to determine if there are some
human stroke patients that have a more severe
chronic inflammatory response to stroke than others.
We recently demonstrated that targeting the B cell re-
sponse to stroke in C57BL/6 mice can prevent the devel-
opment of delayed cognitive deficits. Identifying human
patients that have an equivalent B cell response to stroke
may lead to significant recovery in this population by tar-
geting B cells in the days following stroke [9].
The sizeable difference in the adaptive immune re-
sponse to stroke in humans and C57BL/6 mice may be
due to the advanced age of the human subjects com-
pared to the young adult age of the C57BL/6 mice used
in the first part of this study. Age has been reported to
attenuate the inflammatory response to stroke in
C57BL/6 mice [42]. To control for this possible con-
found, we compared the inflammatory response to
stroke in both young adult and aged C57BL/6 mice. Al-
though we did see significantly less KC present in the
chronic infarcts of the aged mice, we detected signifi-
cantly more RANTES, and the overall cytokine profile
was unchanged by two-way ANOVA.
Surprisingly, in association with the increased amount
of the T cell chemoattractant RANTES, there were fewer
T cells within the infarcts of the aged mice compared to
the young adult mice. This attenuated T cell response
reinforces Sieber and colleagues’ findings that age atten-
uates the inflammatory response to stroke [42]. How-
ever, aged mice still had substantially more T cells within
the lesion than humans, and so this attenuation is not
considerable enough to explain the difference in the in-
flammatory response in areas of liquefactive necrosis in
C57BL/6 mice and humans.
The human tissue used in this study came from both
men and women. Our small sample size meant we were
not sufficiently powered to look for individual sex differ-
ences in the inflammatory response to stroke in humans
at each stage of infarct resolution. Therefore, we ana-
lyzed both sexes in combined groups. Nevertheless, to
gather a broad sense of how much overlap there is in
the chronic inflammatory response to stroke in men and
women, we did calculate how well the sexes correlate
with each other at this time-point. Our data revealed a
significant correlation, which demonstrates that there is
congruency in the chronic inflammatory response to
stroke in men and women. The chronic inflammatory
response to stroke also correlated in male and female
C57BL/6 mice. Although these significant correlations
provide an indication of how much overlap there is in
each sex of each species, they do not imply that there
are no sex differences in the inflammatory response to
stroke in mice or humans.
Many of the human samples used in this study came
from individuals that had suffered from multiple strokes.
Consequently, it is possible that mice that have under-
gone multiple strokes could exhibit an inflammatory
profile at the stage of liquefactive necrosis more equiva-
lent to the human samples we analyzed. To test this like-
lihood we investigated the impact of multiple strokes on
the cytokine and chemokine response to stroke in mice.
We discovered that in mice, the inflammatory response
to a recurrent stroke is very similar to the inflammatory
response to a first stroke, although there is a mild ex-
acerbation at 7 weeks post-stroke. This is in accordance
with Clark and colleagues who demonstrated that a mild
ischemic stroke followed by a second mild cerebral
stroke exacerbates brain damage [6]. Nevertheless, the
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comorbidity of recurrent stroke did not make the in-
flammatory response to stroke in mice more similar to
humans.
The findings presented in this study have therapeutic
and diagnostic relevance. The therapeutic relevance is
that extrapolating from the mouse data it appears that
chronic infarcts persist at the stage of liquefactive necro-
sis for months following stroke. During this time there is
a significant elevation of cytokines associated with proin-
flammatory marcophages (as summarized in Table 5).
Therefore, there is a need to more fully characterize the
phenotype of these macrophages in humans, as well as
determine what factors they are producing, and for how
long they produce them, so that they can be more
effectively evaluated as a target for promoting recovery.
The diagnostic relevance is that this study highlights the
need for the development of live imaging techniques
that can accurately differentiate between different stages
of chronic infarct resolution. New methods need to be
developed that not only distinguish liquefactive necrosis
from cystic encephalomalacia, but also further subdivide
these categories into intervening stages. This would
greatly facilitate trials directed at mediating faster and
more reparative infarct resolution in the brain following
stroke.
Conclusions
In conclusion, this study represents the first simultan-
eous characterization of the inflammatory response to
stroke in the human and mouse brain at different stages
of infarct resolution. We reveal important similarities
and differences in the inflammatory response in these
two species that will help in the selection and validation
of targets for improving stroke recovery. Our findings
reiterate the importance of taking strain into consider-
ation when evaluating the inflammatory response to
stroke, and demonstrate that not only are there import-
ant species and strain differences that should be taken
into consideration when planning preclinical and clinical
research, but that there are also differences in the in-
flammatory response depending on age and prior stroke
history.
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